After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Health Catalyst Inc (HCAT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.17, or 2.04%, to $8.51. The Health Catalyst Inc has recorded 15,543 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Health Catalyst to Participate in Upcoming Investor Conference.
HCAT belongs to the Healthcare sector of the NASDAQ while operating in the Health Information Services industry. At the end of the last regular session, the stock closed at $8.34 and fluctuated between $8.37 as its day high and $7.74 as its day low. The current market capitalization of Health Catalyst Inc is $479.97M. A total of 0.75 million shares were traded on the day, compared to an average of 439.60K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, HCAT has seen 0 BUY and 11 SELL insider trades, representing the acquisition of 0 and the disposition of 29,537 shares. Over the last 12 months, there were 23 BUYs and 45 SELLs from insiders. Insiders purchased 470,819 shares during that period but sold 145,864.
In the most recent transaction, Llewelyn Linda sold 1,161 shares of HCAT for 8.33 per share on Oct 16. After the transaction, the Chief People Officer now owns 79,731 company shares. In a previous transaction on Sep 15, Llewelyn Linda sold 1,160 shares at 11.01 per share. HCAT shares that Chief People Officer owns now total 80,892.
Among the insiders who sold shares, Alger Jason disposed of 2,197 shares on Sep 06 at a per-share price of $11.65. This resulted in the Chief Accounting Officer holding 56,942 shares of HCAT after the transaction. In another insider transaction, Landry Benjamin sold 1,157 shares at $11.52 per share on Sep 06. Company shares held by the General Counsel now total 28,187.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for HCAT in the last 3 months, the mean price target is $11.69 with high estimates of $16.00 and low estimates of $8.00. In terms of 52-week highs and lows, HCAT has a high of $15.87 and a low of $6.60.
As of this writing, HCAT has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of $0.02 per share and a lower estimate of -$0.11.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. HCAT’s latest balance sheet shows that the firm has $444.98M in Cash & Short Term Investments as of fiscal 2021. There were $204.61M in debt and $93.05M in liabilities at the time. Its Book Value Per Share was $6.70, while its Total Shareholder’s Equity was $522.10M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HCAT is Buy with a score of 4.00.